GlassScriptPhysician profile
Scott W Love
NPI 1265409197
$5,658.25
in general payments reported to CMS, 2019-2025
28 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.27 · 2020: $184 · 2021: $401 · 2022: $13.05 · 2023: $954 · 2024: $1,997 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,010.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $756.08 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $681.25 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $672.72 | 2021-2025 | |
| Amgen INC. | $656.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $396.43 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $366.61 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $337.28 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.22 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $271.91 | 2021-2025 | Spravato |
| Viiv Healthcare Company | $259.21 | 2024-2025 | Apretude |
| Merck Sharp & Dohme LLC | $158.93 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Gilead Sciences, INC. | $134.19 | 2025 | |
| Glaxosmithkline, LLC. | $97.76 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Amarin Pharma, INC. | $78.22 | 2019-2021 | |
| Exact Sciences Corporation | $74.33 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $70.66 | 2024-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $64.08 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $44.45 | 2024 | Inspire |
| Cranial Technologies, INC | $42.09 | 2021 | |
| Sanofi Pasteur INC. | $38.50 | 2021-2025 | |
| Esperion Therapeutics, INC. | $35.63 | 2025 | Nexletol |
| Sumitomo Pharma America, INC. | $28.47 | 2024 | Gemtesa |
| Allergan, INC. | $23.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $14.73 | 2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $13.05 | 2022 | |
| Eisai INC. | $11.92 | 2020 | |
| Corium, LLC | $4.62 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.